SCHEMBL7147811

SCHEMBL7147811

Nc1nc(OCc2ccccc2)c(Cl)c(-c2ccco2)n1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 15/20 0.52
ADORA1 P30542 7/20 0.52
ADORA2B P29275 2/20 0.49
ADORA3 P0DMS8 2/20 0.49
MGMT P16455 4/20 0.47
CYP3A4 P08684 2/20 0.47
MPO P05164 1/20 0.47
TPO P07202 1/20 0.47
EPX P11678 1/20 0.47
CDK1 P06493 2/20 0.46
CCNB1 P14635 2/20 0.46
CCNA2 P20248 2/20 0.46
CDK2 P24941 2/20 0.46
CCNA1 P78396 2/20 0.46
LMNA P02545 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
NFKB1 P19838 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5040124 0.88 ADORA2A (0.51) ADORA2AADORA1ADORA2BADORA3MPO
SCHEMBL5041651 0.87 ADORA2A (0.53) ADORA2AADORA1ADORA2BADORA3MPO
SCHEMBL7144843 0.85 ADORA2A (0.49) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL7147379 0.85 ADORA2A (0.49) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL7149520 0.84 ADORA2A (0.51) ADORA2AADORA1ADORA2BADORA3MGMT
SCHEMBL5039831 0.82 MGMT (0.65) ADORA2AADORA1MGMTCDK1CCNB1
SCHEMBL5046632 0.82 ADORA2A (0.62) ADORA2AADORA1ADORA2BADORA3MGMT
Ammonia Solution, Strong SCHEMBL7147942 0.77 ADORA2A (0.51) ADORA2AADORA1ADORA2BADORA3
SCHEMBL7397486 0.75 PDE5A (0.51) ADORA2AADORA1ADORA2BADORA3
SCHEMBL5036755 0.75 ALDH1A1 (0.54) ADORA2AADORA1ADORA2BADORA3MPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6586441-B2 2-Amino-6-benzylsulfanyl-4-thiophen-2-yl-pyridine-3,5-dicarbo -nitrile as an examplary preferred compound; Alzheimer's and Parkinson's diseases; neuroprotectors; schizophrenia, analgesics; anxiolytic agents; respiratory disorders HOFFMAN-LA ROCHE INC. 2003-07-01 US disclosed
EP-1261327-A2 ADENOSINE RECEPTOR MODULATORS F.HOFFMANN-LA ROCHE AG (CH) 2002-12-04 EP disclosed
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease F. HOFFMANN-LA ROCHE AG (CH) 2001-10-04 US disclosed
WO-2001062233-A2 ADENOSINE RECEPTOR MODULATORS F. HOFFMANN LA ROCHE AG (CH) 2001-08-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010027196-A1 Adenosine receptor ligands and their use in the treatment of disease ADORA2A, ADORA2B, ADORA1 ADORA2A 1/4885ADORA1 3/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.